The MOSAIC case control study published in the Lancet Neurology recruited children from the UK National Meningococcal Registry between May, 2008, and September, 2010. Survivors of serogroup B meningococcal disease aged 1 month to 13 years at disease were compared to matched controls for physical, psychological, neurocognitive, and educational outcomes. The researchers showed that most children survive serogroup B meningococcal disease without major sequelae. However, about a tenth have major disabling deficits and more than a third have one or more deficits in physical, cognitive, and psychological functioning, with the additional burden of memory deficits and executive function problems. They hope their findings will not only help to guide assessments of new vaccines but they go on to suggest all survivors of serogroup B meningococcal disease should be screened for psychological disorders and cognitive deficits in addition to hearing loss.
Viner et al The Lancet Neurology, Volume 11, Issue 9, Pages 774 - 783, September 2012 doi:10.1016/S1474-4422(12)70180-1